Abstract | BACKGROUND: Despite their limited licensed indications, anti-interleukin-1 (anti-IL-1) agents are often used in clinical practice for an increasing number of auto-inflammatory diseases. We conducted a national cross-sectional observational study from January 2011 to January 2013 to record the off-label use of such agents in France. We aimed to estimate the off-label use of anti-IL-1 treatments in France, assess their efficacy in rare diseases, and increase the reporting of their possible side effects. METHODS: Physicians answered a questionnaire that covered patient and disease data, anti-IL-1 agent use, efficacy and adverse events. The study involved adult or paediatric patient who had received an anti-IL-1 agent after January 2005 in France. RESULTS: In total, 189 patients from 38 centres were included. The main diseases were adult-onset Still's disease (AOSD) (35), gout (28), systemic juvenile idiopathic arthritis (27), cryopyrin-associated periodic syndrome (CAPS) (21), familial Mediterranean fever (14) and mevalonate kinase deficiency (12). The main off-label used agent was anakinra, used at least once for 185 patients, with canakinumab used for 25. Anakinra was effective in most patients (90%), with higher complete clinical response rates for Schnitzler's syndrome, gout, CAPS and AOSD. Overall, 58% of patients showed at least one adverse event, mainly minor injection-site reactions. The main reported serious adverse event was severe infection. Injection-site reactions and liver toxicity were significantly more frequent in children than adults. The main non-cutaneous adverse event was liver toxicity, significantly associated with treatment duration. Weight gain was reported in about 10% of patients and was associated with treatment duration and CAPS. Canakinumab was rarely used and showed better cutaneous tolerance than anakinra but similar rates of non-cutaneous and severe adverse events. CONCLUSIONS:
|
Authors | Linda Rossi-Semerano, Bruno Fautrel, Daniel Wendling, Eric Hachulla, Caroline Galeotti, Luca Semerano, Isabelle Touitou, Isabelle Koné-Paut, MAIL1 (Maladies Auto-inflammatoires et Anti-IL-1) study Group on behalf of CRI (Club Rhumatisme et Inflammation) |
Journal | Orphanet journal of rare diseases
(Orphanet J Rare Dis)
Vol. 10
Pg. 19
(Feb 15 2015)
ISSN: 1750-1172 [Electronic] England |
PMID | 25758134
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Antibodies, Monoclonal
- Antibodies, Monoclonal, Humanized
- Interleukin 1 Receptor Antagonist Protein
- Interleukin-1
- canakinumab
|
Topics |
- Adolescent
- Adult
- Aged
- Aged, 80 and over
- Antibodies, Monoclonal
(administration & dosage, adverse effects, therapeutic use)
- Antibodies, Monoclonal, Humanized
- Autoimmune Diseases
(drug therapy, immunology)
- Child
- Child, Preschool
- Cross-Sectional Studies
- Female
- France
- Humans
- Infant
- Inflammation
(drug therapy, immunology)
- Interleukin 1 Receptor Antagonist Protein
(administration & dosage, adverse effects, therapeutic use)
- Interleukin-1
(antagonists & inhibitors)
- Male
- Middle Aged
- Off-Label Use
(statistics & numerical data)
- Young Adult
|